Troxerutin Encyclopedia — Scientific Background

What Is Troxerutin?

Troxerutin (CAS 7085-55-4), also known as trihydroxyethylrutin, 3′,4′,7-tris[O-(2-hydroxyethyl)]rutin, or vitamin P4, is a semi-synthetic bioflavonoid derived from rutin, a natural flavonoid extracted from Sophora japonica. It belongs to the hydroxyethylrutoside class of compounds, which are semi-synthetic derivatives of rutin and a mixture of mono-, di-, and tri-hydroxyethylated rutosides. Troxerutin is a fraction of oxerutine, the standard mixture of hydroxyethylrutosides used for the treatment of chronic venous insufficiency.

Botanical Source

Troxerutin is derived from rutin, a natural flavonoid glycoside extracted from the buds of Sophora japonica (Japanese pagoda tree). Rutin is extracted and transformed to troxerutin through a semi-synthetic hydroxyethylation process. Sophora japonica is a plant used in traditional Chinese medicine, and its buds are a rich source of rutin.

Mechanisms of Action

Vasoprotective and Phlebotonic Activity

Troxerutin inhibits the agglomeration of blood platelets and red blood cells, prevents thrombogenesis, protects endothelial cells, and enhances microcirculation. It has demonstrated effects on capillary permeability, erythrocyte deformation and aggregation, antiedematous actions, and inhibition of prostaglandin synthesis. Its diffusion and accumulation in the venous wall have been demonstrated, and it is indicated as an antiedematous agent in venous disorders, proctology (hemorrhoids), and ophthalmology (retinopathy).

Antioxidant Defense — Nrf2/ARE Pathway

Troxerutin exerts its antioxidant functions through direct free radical scavenging activity and by enhancing the activity of Glutathione and antioxidant enzymes. It increases the nuclear translocation of nuclear factor erythroid 2-related factor 2 (Nrf2) and downregulates nuclear factor κB (NF-κB). Troxerutin also reduces acetylcholinesterase activity and upregulates the phosphoinositide 3-kinase/Akt signaling pathway.

Anti-Inflammatory Activity

Troxerutin has been shown to ameliorate tissue injury by inhibiting MAPK and NF-κB signaling pathways. It protects against liver inflammation by attenuating oxidative stress-mediated NAD+ depletion.

Additional Pharmacological Activities

Troxerutin has been reported to exert several pharmacological effects including antioxidant, anti-inflammatory, antihyperlipidemic, and nephroprotective activities. It has been investigated for therapeutic potential against neurodegenerative, diabetic, cancer, and cardiovascular diseases.

The Bioavailability Challenge

Despite its established clinical efficacy, troxerutin presents significant formulation challenges. The compound exhibits poor oral bioavailability and rapid plasma clearance, limiting its clinical efficacy and requiring high doses to achieve therapeutic effects. Following oral administration, troxerutin is absorbed from the gastrointestinal tract with a time to peak concentration of 1–6 hours, plasma protein binding of approximately 30%, and an elimination half-life of 10–25 hours. Approximately 70% of metabolites are excreted in feces, and enterohepatic circulation may occur.

A comparative pharmacokinetic study in male Wistar rats evaluated a water-in-oil microemulsion formulation of troxerutin to improve oral bioavailability. The optimal formulation consisted of lecithin, ethanol, isopropyl myristate, and water (23.30/11.67/52.45/12.59 w/w), with a mean droplet size of approximately 50.20 nm. In vitro studies using MDCK cell monolayers demonstrated higher intestinal membrane permeability compared with control solution. In vivo, the microemulsion significantly promoted intestinal absorption of troxerutin, achieving a relative bioavailability of approximately 205.55% compared to control solution.

Liposomal Troxerutin

liposomal encapsulation of troxerutin provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the troxerutin molecule, forming a shield that protects it from enzymatic degradation and premature metabolism in the gastrointestinal tract. This delivery system:

• Protects troxerutin from rapid plasma clearance and hepatic metabolism

• Enhances intestinal absorption through lipid-mediated pathways

• Improves cellular uptake through membrane fusion

• Provides sustained release for prolonged vasoprotective activity

Liposomal troxerutin formulations have been developed for both oral and topical applications. Phyto-liposomes encapsulating troxerutin and vitamin E acetate have been designed for cosmetic and dermopharmaceutical applications, utilizing nanovectors to enhance penetration through the stratum corneum and improve phlebotonic activity. A new reversible complex between troxerutin and phosphatidylcholine in the form of a liposome-like water microdispersion has been evaluated for topical treatment of acute lymphedema, demonstrating promising anti-edematous effects.

Clinical Evidence

Chronic Venous Insufficiency

A comparative clinical study evaluated the effectiveness of troxerutin in association with pycnogenol for the pharmacological treatment of venous insufficiency. The first group received troxerutin (470 mg) associated with pycnogenol (20 mg) at a dose of 1 g/day orally for 60 days, while the second group received troxerutin alone (300 mg) at a dose of 2 tablets twice daily for 60 days. The study demonstrated the clinical efficacy of troxerutin in managing venous insufficiency symptoms.

Varicose Veins

A clinical study investigated the effect of short-term oral dihydroergotamine and troxerutin in patients with varicose veins. Patients received either a fixed combination of 3 mg dihydroergotamine and 300 mg troxerutin three times a day or placebo for 3 weeks. The study evaluated the effects of troxerutin on venous symptoms and demonstrated its therapeutic potential in varicose vein management.

Safety Profile

In a double-blind, placebo-controlled study involving 231 patients who took either placebo or a combination of coumarin 30 mg + troxerutin 180 mg three times daily, there were no serious adverse drug reactions reported. There was a 4.9% risk of abnormal liver function tests compared with a 2.1% risk with placebo, with a history of hepatitis or other liver diseases identified as a susceptibility factor. A few cases of yellow discoloration of the skin (but not of the sclerae) have been observed, which can be mistaken for jaundice; the discoloration vanishes when the drug is withdrawn. Troxerutin is generally well tolerated at therapeutic doses, with no significant adverse effects reported in clinical trials.

Safety and Regulatory

Troxerutin has an established safety profile based on extensive clinical use. It is approved as a pharmaceutical agent in multiple European countries for the treatment of chronic venous insufficiency. The standard adult dose is 1 g per day, and treatment is generally maintained for 2–3 months until symptom remission. No dosage adjustment is necessary in patients with renal or hepatic impairment or in the elderly. Troxerutin is contraindicated in individuals with hypersensitivity to the active substance or any excipients. Special clinical monitoring is recommended in patients with gastroduodenal ulcer, severe hemorrhage, or thrombocytopenia. Animal studies have not demonstrated teratogenic or fetotoxic effects at doses well above therapeutic levels in humans, and troxerutin does not pass into breast milk in significant amounts. Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

129$/KG

109$/KG